Literature DB >> 6602146

Serum IgE and IgG antibodies to tetanus toxoid and candidin in immunodeficient children with the hyper-IgE syndrome.

C Schmitt, J J Ballet.   

Abstract

Serum IgG and IgE antibodies directed against tetanus toxoid and candidin were measured using a solid-phase radioimmunoassay in seven patients with the immunodeficiency syndrome with hyper-IgE. In parallel, six normal children, three normal adults, and eight patients with or without elevated serum IgE (including atopic diseases, Candida infections, and active schistosomiasis) were studied. Serum IgG antibodies to tetanus toxoid and candidin were present in the hyper-IgE patients in concordance with their immunization history. High concentrations of IgE antibodies against both antigens were found in the immune hyper-IgE patients but not in the controls. This suggests that elevated IgE antibody responses in the hyper-IgE syndrome results from a primary defect of IgE class regulation rather than an abnormal or deficient antibody response.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6602146     DOI: 10.1007/bf00915490

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  20 in total

1.  T lymphocyte dysfunction, hyperimmunoglobulinemia E, recurrent bacterial infections, and defective neutrophil chemotaxis in a Negro child.

Authors:  J A Church; L D Frenkel; D G Wright; J A Bellanti
Journal:  J Pediatr       Date:  1976-06       Impact factor: 4.406

2.  In vitro production of IgE by lymphocytes from a patient with hyperimmunoglobulinaemia E, eosinophilia and increased lymphocytes carrying surface IgE.

Authors:  R Patterson; I M Suszko; C C Hsu; M Roberts; S H Oh
Journal:  Clin Exp Immunol       Date:  1975-05       Impact factor: 4.330

Review 3.  Stimuli for the production and control of IgE in rats.

Authors:  E E Jarrett
Journal:  Immunol Rev       Date:  1978       Impact factor: 12.988

Review 4.  Abnormalities in the regulation of human IgE synthesis.

Authors:  R H Buckley; W G Becker
Journal:  Immunol Rev       Date:  1978       Impact factor: 12.988

5.  Defective neutrophil chemotaxis and cellular immunity in a child with recurrent infections.

Authors:  R A Clark; R K Root; H R Kimball; C H Kirkpatrick
Journal:  Ann Intern Med       Date:  1973-04       Impact factor: 25.391

6.  Raised serum-IgE levels and defective neutrophil chemotaxis in three children with eczema and recurrent bacterial infections.

Authors:  H R Hill; P G Quie
Journal:  Lancet       Date:  1974-02-09       Impact factor: 79.321

7.  IgE antibodies to Staphylococcus aureus and Candida albicans in patients with the syndrome of hyperimmunoglobulin E and recurrent infections.

Authors:  M Berger; C H Kirkpatrick; P K Goldsmith; J I Gallin
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

8.  Human IgE synthesis in vitro: a reassessment.

Authors:  H A Sampson; R H Buckley
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

9.  Subpopulations of human T lymphocytes. XVIII. T lymphocytes with receptors for IgE (T epsilon) in patients with primary immunodeficiency and hyperimmunoglobulinaemia E states.

Authors:  S Gupta
Journal:  Clin Exp Immunol       Date:  1981-07       Impact factor: 4.330

10.  IgE synthesis in man. I. Development of specific IgE antibodies after immunization with tetanus-diphtheria (Td) toxoids.

Authors:  J Nagel; D Svec; T Waters; P Fireman
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

View more
  3 in total

Review 1.  Cutaneous defenses against dermatophytes and yeasts.

Authors:  D K Wagner; P G Sohnle
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

2.  Immunoglobulins in the hyperimmunoglobulin E and recurrent infection (Job's) syndrome. Deficiency of anti-Staphylococcus aureus immunoglobulin A.

Authors:  S C Dreskin; P K Goldsmith; J I Gallin
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

Review 3.  The hyper-IgE syndrome.

Authors:  R H Buckley
Journal:  Clin Rev Allergy Immunol       Date:  2001-02       Impact factor: 10.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.